Nuvectis Pharma Reports Third Quarter 2026 Financial Results
Nuvectis Pharma reported a net loss of $30.1 million for the third quarter of 2026 and announced the in-licensing of ex-China rights for two drug candidates.
Stocks · News reference
Nuvectis Pharma Announces Positive Expanded Data from Phase 1b Study of NXP200
Nuvectis Pharma, Inc. reported positive, expanded data from its Phase 1b clinical study of NXP200, a second-generation, paradox-breaker BRAF inhibitor, in patients with recurrent or progressive BRAF V600-mutated tumors.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K filing — Nuvectis Pharma, Inc. (NVCT)
Filed: 2026-11-04 AccNo: 0001104659-26-122360 Size: 326 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Nuvectis Pharma Schedules Third Quarter 2026 Financial Results Announcement
Nuvectis Pharma, Inc. announced that it will release its financial results for the third quarter of 2026 on November 4, 2026.
Nuvectis Pharma to Report Third Quarter 2026 Financial Results on November 4, 2026
Nuvectis Pharma announced it will host a conference call on November 4, 2026 at 8:00 AM ET to discuss Q3 2026 business progress and financial results. The clinical-stage biopharmaceutical company is focused on developing therapies for complement-related conditions and oncology, with lead candidate NXP100 (ciprocopan) recently approved in China for PNH treatment.
HC Wainwright & Co. Reiterates Buy on Nuvectis Pharma, Maintains $39 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates Nuvectis Pharma (NASDAQ:NVCT) with a Buy and maintains $39 price target.
Nuvectis Pharma's NXP200 BRAF Inhibitor Receives China's Breakthrough Therapy Designation
Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative therapies for the treatment of complement-related